how cryptocurrency created Top Knowledge

The second meeting of the Global Foreign Exchange Market Committee in 2024 was successfully held. From December 5 to December 6, 2024, the second meeting of the Global Foreign Exchange Committee (GFXC) in 2024 was held online. The meeting discussed the promotion and implementation of global standards, the second round of three-year review of global standards, the operation of foreign exchange market and related market hot issues. Representatives from China Foreign Exchange Market Steering Committee (CFXC) attended the meeting. This meeting discussed the final results of the second round of three-year review of global standards. The Working Group on Foreign Exchange Settlement Risk and the Working Group on Foreign Exchange Data respectively introduced the final revision suggestions of the relevant provisions of the global standards, and how the Working Group continuously improved according to the public comments and feedback from the local foreign exchange market committees and in October 2024. The revision of the Global Standards aims to strengthen the relevant principles of foreign exchange settlement risk management and enhance the transparency of specific types of foreign exchange transactions and the use of customer-generated data on electronic trading platforms. GFXC members strongly support this.Sarah Friar, CFO of OpenAI: Corporate customers will pay (at least) thousands of dollars for using artificial intelligence (AI) tools. In the end, it will be reasonable.New World Development sold Artisan Lab in Kowloon, Hong Kong for HK$ 620 million. Sing Tao Daily quoted an unnamed insider as saying that New World Development sold Artisan Lab in San Po Kong, Kowloon for HK$ 620 million. This 22-storey building was completed in 2022, with a floor area of about 120,000 square feet.

Monetary policy has turned to "moderate easing", and experts say that it is expected to make greater efforts to lower the RRR and cut interest rates. The the Political Bureau of the Communist Party of China (CPC) Central Committee meeting held on December 9 changed the orientation of monetary policy from "steady" to "moderate easing" next year. Experts said that under the orientation of "moderate easing", the monetary policy space was further opened. In terms of total amount, it is more reasonable and sufficient to maintain liquidity; In terms of price, appropriately reducing the financing cost will better reflect the effectiveness of monetary policy. Next year, even greater RRR cuts and interest rate cuts can be expected. In addition to lowering the RRR and cutting interest rates, experts said that structural monetary policy tools, buying government bonds, open market buyout reverse repurchase and other operations are expected to continue to expand the scale, increase the frequency of use, and continuously enhance the effectiveness and pertinence of monetary policy. (CSI)Hengrui Pharma: HRS-4729 injection was approved for clinical trial. Hengrui Pharma announced that the company and its subsidiary Fujian Sheng Di Pharmaceutical Co., Ltd. received the Notice of Approval for Clinical Trial of HRS-4729 injection approved and issued by National Medical Products Administration. The drug is a polypeptide drug independently developed, and it is a GLP-1R/GIPR/GCGR triple agonist, which is suitable for obese or overweight patients. Up to now, HRS-4729 injection has invested about 19.56 million yuan in research and development.Bank of America: Resume the coverage of Lilly and give it a "buy" rating with a target price of $997.

Putin had a phone conversation with Hungarian President Orban on the situation in Ukraine. According to the Tass news agency, Russian President Vladimir Putin and Hungarian Prime Minister Orban discussed the further development of energy projects.Hengrui Pharma: HRS-4729 injection was approved for clinical trial. Hengrui Pharma announced that the company and its subsidiary Fujian Sheng Di Pharmaceutical Co., Ltd. received the Notice of Approval for Clinical Trial of HRS-4729 injection approved and issued by National Medical Products Administration. The drug is a polypeptide drug independently developed, and it is a GLP-1R/GIPR/GCGR triple agonist, which is suitable for obese or overweight patients. Up to now, HRS-4729 injection has invested about 19.56 million yuan in research and development.Russian Foreign Ministry Spokesperson Zacharova: The Russian Federation keeps in touch with all political forces in Syria. The Russian Federation is holding an operational headquarters meeting to discuss the security of Russians and Russian facilities in Syria.